CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

Core Insights - CERo Therapeutics Holdings, Inc. is presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference from November 5-9, 2025 [1] - The poster presentation highlights preclinical data demonstrating the sustained effector function and resistance to exhaustion of CER-1236, showing durability of activity compared to traditional stimulation methods [2] - The CEO of CERo expressed confidence in the data supporting the ongoing Phase 1 trial, which aims to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, integrating both innate and adaptive immunity in its approach [4] - The company’s proprietary platform, which includes Chimeric Engulfment Receptor T cells (CER-T), aims to enhance tumor targeting capabilities compared to existing CAR-T therapies [4] - CERo has initiated clinical trials for CER-1236 specifically targeting hematologic malignancies [4]